In our present day of fast life (which ironically is mostly sedentary), and poor diet options, it has become increasingly more difficult to watch weight, and even more difficult to lose it, and one company is taking advantage of this rather peculiar opportunity to make billions of dollars!
The increasing global need for weight-loss remedies has significantly boosted the fortunes of Novo Nordisk, a pharmaceutical company now valued higher than Denmark's entire economy. This surge in value is attributed to the company's dominance in the U.S. market, being the sole FDA-approved producer of a highly successful pharmaceutical known as semaglutide. This compound is the active ingredient in Ozempic, a treatment for Type 2 diabetes, and Wegovy, a solution for obesity. Notably, even Elon Musk is benefiting from Wegovy's weight loss effects.
Novo Nordisk's value has tripled since 2020, surpassing $400 billion, and it's on track to challenge LVMH as Europe's biggest company. The company's CEO, Lars Fruergaard Jørgensen, reported an increasing number of patients being served and heightened sales due to the growing demand for semaglutide treatments.
Semaglutides function by boosting insulin production and also influencing parts of the brain related to appetite control, contributing to feelings of fullness. In the first half of 2023, Novo Nordisk helped 39 million people address diabetes and weight issues, reflecting a rise in sales by nearly a third. The popularity of Wegovy in the U.S. played a significant role in this remarkable 157% surge in obesity care demand.
The market value of Novo Nordisk increased sharply, surpassing the GDP of Denmark as a result of a ground-breaking study that showed Wegovy reduces the risk of heart attacks and strokes by 20%.
These findings could very well revolutionize the way obesity is view from now on, not just a state in which a person is and should be respected, but as a disease whose cure is now possible.
Meanwhile, somewhere in Nigeria where food is being sold right inside a gym😄
I bet people like this wouldn't think twice about becoming customers so they don't have to go through stress of exercising.
With the alarming prevalence of obesity, Novo Nordisk's injectables gained prominence for reducing weight by around 15% when combined with lifestyle changes. Ozempic received FDA approval for Type 2 diabetes treatment in 2017, while Wegovy gained approval in 2021, becoming the first weight-loss drug to be approved by the FDA in eight years. Its effectiveness and ensuing demand led to supply restrictions for starter doses, with supply shortages expected in the coming months.
In response to the demand-supply gap, unauthorized versions of Ozempic and Wegovy have appeared, which shouldn't be surprising given that these drugs have proven to be a valuable option to those who view it as a medical marvel that can solve all their weight related troubles.
https://www.ft.com/content/710c1048-7717-4553-a831-9e13ff27fb6c
https://fortune.com/2023/08/11/weight-loss-diabetes-ozempic-wegovy-elon-musk-novo-nordisk-denmark/
Thanks for reading, if you found my post interesting, then remember to hit the follow button so you don’t miss out on future posts. I look forward to your contributions in the comment section.
My name is Edwin Ifeanyi Louis (eil7304) and I love to write about finance and investing, movies, technology, gaming, fiction and just about any topic that piques my interest on a Blockchain platform called Hive.
